Role of Leptin in Cardiovascular Diseases
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
The adipocyte-derived adipokine leptin exerts pleiotropic effects, which are essential for the regulation of energy balance and cell metabolism, for controlling inflammatory and immune responses, and for the maintenance of homeostasis of the cardiovascular system. Leptin resistance in obese or type 2 diabetes mellitus (T2DM) patients is defined as a decrease in tissue response to leptin. In the cardiovascular system, leptin resistance exhibits the adverse effect on the heart's response to stress conditions and promoting cardiac remodeling due to impaired cardiac metabolism, increased fibrosis, vascular dysfunction, and enhanced inflammation. Leptin resistance or leptin signaling deficiency results in the risk increase of cardiac dysfunction and heart failure, which is a leading cause of obesity- and T2DM-related morbidity and mortality. Animal studies using leptin- and leptin receptor- (Lepr) deficient rodents have provided many useful insights into the underlying molecular and pathophysiological mechanisms of obese- and T2DM-associated metabolic and cardiovascular diseases. However, none of the animal models used so far can fully recapitulate the phenotypes of patients with obese or T2DM. Therefore, the role of leptin in the human cardiovascular system, and whether leptin affects cardiac function directly or acts through a leptin-regulated neurohumoral pathway, remain elusive. As the prevalence of obesity and diabetes is continuously increasing, strategies are needed to develop and apply human cell-based models to better understand the precise role of leptin directly in different cardiac cell types and to overcome the existing translational barriers. The purpose of this review is to discuss the mechanisms associated with leptin signaling deficiency or leptin resistance in the development of metabolic and cardiovascular diseases. We analyzed and comprehensively addressed substantial findings in pathophysiological mechanisms in commonly used leptin- or Lepr-deficient rodent models and highlighted the differences between rodents and humans. This may open up new strategies to develop directly and reliably applicable models, which resemble the human pathophysiology in order to advance health care management of obesity- and T2DM-related cardiovascular complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans
Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W., Nyce, M. R., Ohannesian, J. P., Marco, C. C., McKee, L. J., Bauer, T. L., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340503 · Cited by 6,326
Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., de Ferranti, S., Després, J.-P., Fullerton, H. J., Howard, V. J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000152 · Cited by 5,797
Spironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809 · cited 4×
“This explains why the aldosterone antagonist spironolactone is particularly effective in reducing morbidity andmortality in patients with obesity-related HFpEF (113).”
BackgroundInfluentialA mutation in the human leptin receptor gene causes obesity and pituitary dysfunction
Clément, K., Vaisse, C., Lahlou, N., Cabrol, S., Pelloux, V., Cassuto, D., Gourmelen, M., Dina, C., Chambaz, J., Lacorte, J.-M., et al. (1998) · Nature · doi:10.1038/32911 · Cited by 2,346 · cited 1×
“2597+1G>A), which results in the exon 16 skipping and premature termination of protein synthesis (39).”
BackgroundAbnormal splicing of the leptin receptor in diabetic mice
Lee, G.-H., Proenca, R., Montez, J. M., Carroll, K. M., Darvishzadeh, J. G., Lee, J. I., & Friedman, J. M. (1996) · Nature · doi:10.1038/379632a0 · Cited by 2,327
Diabetic Cardiomyopathy Revisited
Boudina, S., & Abel, E. D. (2007) · Circulation · doi:10.1161/circulationaha.106.679597 · Cited by 1,543
Lipotoxic heart disease in obese rats: Implications for human obesity
Zhou, Y.-T., Grayburn, P., Karim, A., Shimabukuro, M., Higa, M., Baetens, D., Orci, L., & Unger, R. H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1784 · Cited by 1,265
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Farooqi, I. S., Matarese, G., Lord, G. M., Keogh, J. M., Lawrence, E., Agwu, C., Sanna, V., Jebb, S. A., Perna, F., Fontana, S., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215693 · Cited by 1,105
Leptin in the regulation of immunity, inflammation, and hematopoiesis
Fantuzzi, G., & Faggioni, R. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.68.4.437 · Cited by 980 · cited 1×
“Administration of recombinant leptin substantially increased thymic cellularity and restored abnormalities in proliferating T cells and cytokine release of immune cells in ob/ob mice and humans with leptin deficiency (40, 56, 58, 59).”
BackgroundThe weight of leptin in immunity
Cava, A. L., & Matarese, G. (2004) · Nature Reviews Immunology · doi:10.1038/nri1350 · Cited by 927 · cited 1×
“Leptin modulates the immune response and inflammation at various levels, which have been detailed reviewed previously (46, 47) and are discussed here only briefly.”
BackgroundObesity, inflammation and the immune system
de Heredia, F. P., Gómez-Martínez, S., & Marcos, A. (2012) · Proceedings of the Nutrition Society · doi:10.1017/s0029665112000092 · Cited by 845 · cited 2×
“Higher concentrations of pro-inflammatory cytokines have also been detected in individuals who are insulin resistant and obese and are used to predict the development of T2DM and cardiovascular diseases (43, 45).”
BackgroundIntramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart
Sharma, S., Adrogue, J. V., Golfman, L., Uray, I., Lemm, J., Youker, K., Noon, G. P., Frazier, O. H., & Taegtmeyer, H. (2004) · The FASEB Journal · doi:10.1096/fj.04-2263com · Cited by 790 · cited 1×
“Obese patients with insulin resistance display high levels of myocardial triglycerides, which are linked to transcriptional upregulation of PPARα-regulated genes, myosin heavy chain β (β-MHC), and TNF-α, in addition to cardiac contractile dysfunction (82, 104).”
BackgroundClinical and molecular genetic spectrum of congenital deficiency of the leptin receptor.
Farooqi, I. S., Wangensteen, T., Collins, S., Kimber, W., Matarese, G., Keogh, J. M., Lank, E., Bottomley, B., Lopez-Fernandez, J., Ferraz-Amaro, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063988 · Cited by 732
Mitochondrial Energetics in the Heart in Obesity-Related Diabetes
Boudina, S., Sena, S., Theobald, H., Sheng, X., Wright, J. J., Hu, X. X., Aziz, S., Johnson, J. I., Bugger, H., Zaha, V. G., et al. (2007) · Diabetes · doi:10.2337/db07-0481 · Cited by 586
Takeda, K., Kaisho, T., Yoshida, N., Takeda, J., Kishimoto, T., & Akira, S. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.9.4652 · Cited by 584
Huby, A.-C., Antonova, G., Groenendyk, J., Gomez-Sanchez, C. E., Bollag, W. B., Filosa, J. A., & de Chantemèle, E. J. B. (2015) · Circulation · doi:10.1161/circulationaha.115.018226 · Cited by 376 · cited 1×
“Leptin, Cardiac Fibrosis, and Vascular Dysfunction Leptin-mediated aldosterone production is considered a novel mechanism of obesity-associated endothelial dysfunction and cardiac fibrosis, which impair myocardial relaxation and thereby contribute to cardiovascular disease (112).”
BackgroundCardiac Lipid Accumulation Associated with Diastolic Dysfunction in Obese Mice
Christoffersen, C., Bollano, E., Lindegaard, M. L. S., Bartels, E. D., Goetze, J. P., Andersen, C. B., & Nielsen, L. B. (2003) · Endocrinology · doi:10.1210/en.2003-0242 · Cited by 375
Williams, K. W., Margatho, L. O., Lee, C. E., Choi, M., Lee, S., Scott, M. M., Elias, C. F., & Elmquist, J. K. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3118-09.2010 · Cited by 352
Barouch, L. A., Berkowitz, D. E., Harrison, R. W., O’Donnell, C. P., & Hare, J. M. (2003) · Circulation · doi:10.1161/01.cir.0000083716.82622.fd · Cited by 341 · cited 2×
“Interestingly, while either leptin administration or caloric restriction resulted in weight loss in ob/ob mice, leptin infusion but not caloric restriction reversed the obesity-related cardiac remodeling process, indicating that leptin has anti-hypertrophic effects not attributable to weight loss alone (70).”
BackgroundMethodChronic Cardiovascular and Renal Actions of Leptin: Role of Adrenergic Activity
Carlyle, M., Jones, O. B., Kuo, J. J., & Hall, J. E. (2002) · Hypertension · doi:10.1161/hy0202.104398 · Cited by 292
Sweeney, G. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(02)00006-2 · Cited by 271
Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice
Semeniuk, L. M., Kryski, A. J., & Severson, D. L. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00088.2002 · Cited by 266 · cited 2×
“In particular, db/db mice develop both systolic and diastolic dysfunctions and contractile abnormalities, but with maintenance of cardiac output by favorable loading conditions (increased preload and decreased afterload) at 12 weeks of age (72, 73).”
BackgroundObesity, Diabetes, and Cardiovascular Diseases: A Compendium
Scherer, P. E., & Hill, J. A. (2016) · Circulation Research · doi:10.1161/circresaha.116.308999 · Cited by 237
Xu, F.-P., Chen, M.-S., Wang, Y.-Z., Yi, Q., Lin, S.-B., Chen, A. F., & Luo, J.-D. (2004) · Circulation · doi:10.1161/01.cir.0000140766.52771.6d · Cited by 234 · cited 1×
“(MMP-2) activity, and endothelin-1-induced rise in ROS levels (106, 107).”
BackgroundExpression of leptin receptors and response to leptin stimulation of human natural killer cell lines
Zhao, Y., Sun, R., You, L., Gao, C., & Tian, Z. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02838-3 · Cited by 229
Dexamethasone increases leptin expression in humans in vivo
Papaspyrou-Rao, S., Schneider, S. H., Petersen, R. N., & Fried, S. K. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.5.3928 · Cited by 185 · cited 1×
“Similar, glucocorticoids increase leptin mRNA and plasma leptin levels, but as they cause insulin resistance and hyperinsulinemia, the effect of glucocorticoids on leptin levels may be indirect (30).”
BackgroundGong, Y., Ishida-Takahashi, R., Villanueva, E. C., Fingar, D. C., Münzberg, H., & Myers, M. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702838200 · Cited by 173 · cited 1×
“Phosphorylation of Tyr1077 promotes recruitment and activation of STAT5 (20, 21), whereas phosphorylation on Tyr1138 results in recruitment and activation of STAT1/5 and STAT3, which permit auto-phosphorylation of STAT proteins (20).”
BackgroundXu, L., & Ota, T. (2017) · Adipocyte · doi:10.1080/21623945.2017.1413516 · Cited by 134 · cited 1×
“SGLT2 inhibitors are known not only to improve cardiac function and metabolism, but also to promote weight loss by reducing visceral fat depots and to attenuate the obesity-induced inflammatory response and insulin resistance by modulating the activity of M2macrophages (109, 110).”
BackgroundMADANI, S., DEGIROLAMO, S., MUNOZ, D., LI, R., & SWEENEY, G. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.11.022 · Cited by 122 · cited 1×
“(MMP-2) activity, and endothelin-1-induced rise in ROS levels (106, 107).”
BackgroundWang, P., Lloyd, S. G., Zeng, H., Bonen, A., & Chatham, J. C. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00935.2004 · Cited by 118 · cited 1×
“Similar to mouse models, impaired leptin signaling also contributes to the cardiac-specific phenotype in fa/fa and ZDF rats, as illustrated by LV hypertrophy and defects in cardiac contractility, such as reduced fractional shortening, yet these effects are less pronounced in fa/fa rats (76, 77).”
BackgroundFibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade
Kosmala, W., Przewlocka-Kosmala, M., Szczepanik-Osadnik, H., Mysiak, A., & Marwick, T. H. (2013) · Heart · doi:10.1136/heartjnl-2012-303329 · Cited by 104
Golfman, L. S., Wilson, C. R., Sharma, S., Burgmaier, M., Young, M. E., Guthrie, P. H., Van Arsdall, M., Adrogue, J. V., Brown, K. K., & Taegtmeyer, H. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00055.2005 · Cited by 99 · cited 2×
“Administration of a peroxisome proliferatoractivated receptor γ (PPARγ) agonist to ZDF rats resulted in an increase in glucose metabolism, reduced accumulation of triacylglycerol in the myocardium, and restored cardiac function (76).”
BackgroundCarley, A. N., Semeniuk, L. M., Shimoni, Y., Aasum, E., Larsen, T. S., Berger, J. P., & Severson, D. L. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00329.2003 · Cited by 94 · cited 1×
“Although chronic administration of db/db mice with a PPARγ agonist induced insulin sensitization, enhanced glucose oxidation, and decreased palmitate oxidation, it failed to restore cardiac function (87).”
BackgroundMagnetic resonance imaging of progressive cardiomyopathic changes in the db/db mouse
Yue, P., Arai, T., Terashima, M., Sheikh, A. Y., Cao, F., Charo, D., Hoyt, G., Robbins, R. C., Ashley, E. A., Wu, J., et al. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00856.2006 · Cited by 81 · cited 1×
“Animal Models for Leptin and Leptin Receptor Deficiency and Cardiovascular Diseases Animal models have helped to understand leptin signaling in the heart (69) and both ob/ob and db/dbmice show an age-dependent progression of hypertrophy, mostly effecting left ventricular (LV) mass and LV wall thickness (70, 71).”
MethodHafstad, A. D., Khalid, A. M., How, O.-J., Larsen, T. S., & Aasum, E. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00504.2006 · Cited by 79
Van den Bergh, A., Flameng, W., & Herijgers, P. (2006) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2006.03.001 · Cited by 68
Targeting obesity and diabetes to treat heart failure with preserved ejection fraction
Altara, R., Giordano, M., Nordén, E. S., Cataliotti, A., Kurdi, M., Bajestani, S. N., & Booz, G. W. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00160 · Cited by 61
Balland, E., Chen, W., Dodd, G. T., Conductier, G., Coppari, R., Tiganis, T., & Cowley, M. A. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.061 · Cited by 44 · cited 3×
“The central pharmacological inhibition or ARC-targeted deletion of PTP1B restores insulin-mediated suppression of hepatic glucose production in obese mice (7).”
Background
Metadata
- Authors
- Poetsch, M. S., Strano, A., & Guan, K.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2020-06-16
- Volume
- 11
- Pages
- 354-354
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W3035843830
- Cited by
- 171
- References
- 40
- FWCI
- 14.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.